Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs provides affinity-purified anti-pupylation antibodies specifically validated for detecting, confirming, and measuring protein pupylation events. These antibodies derive from our proprietary High-Affi™ platform, which employs synthetic antigens combining carrier proteins with strategically positioned prokaryotic ubiquitin-like protein (Pup)-modified residues to ensure exceptional specificity.
Pupylation, the prokaryotic post-translational modification (PTM), involves covalently linking the Pup protein to lysine residues on substrate proteins through C-terminal isopeptide bonds. Functionally analogous yet structurally distinct from eukaryotic ubiquitination, pupylation directs proteins toward proteasomal degradation. Its biochemical pathway diverges from ubiquitination's three-step cascade, operating through two enzymatic stages. The process initiates with Pup activation via Dop-mediated deamidation of its terminal glutamine, contrasting with ubiquitin's prerequisite proteolytic cleavage to expose a diglycine motif. PafA then catalyzes attachment of deamidated Pup to substrates, utilizing either α- or γ-carboxyl groups from terminal glutamate residues (GGE). Current evidence remains inconclusive regarding poly-polylation occurrences.
Fig.1 Overview of pathways to pupylation.1
Pupylation reversibility mirrors other PTMs: PafA mediates conjugation while Dop executes removal, preserving substrate and Pup integrity throughout cycling. Although the enzymatic cascade is well-characterized, pupylation's precise contributions to Mycobacterium tuberculosis (Mtb) virulence require further elucidation. Recent studies implicate both pupylation and mycobacterial proteasomes in macrophage evasion strategies, particularly within drug-resistant Mtb strains. These interconnected systems present compelling targets for novel antimicrobial therapies.
Fig.2 The pupylation/depupylation cycle in mycobacteria.2
Utilize our specialized knowledge to create tailored antibodies addressing your pupylation research challenges. Below outlines our core antibody categories and their applications.
Polyclonal Antibodies: These are a diverse mix of antibodies from different immune cells, recognizing multiple epitopes across the Pup modification or its attachment sites. Their broad recognition profile makes them cost-effective initial screening tools for identifying pupylation events.
Monoclonal Antibodies: Sourced from single B-cell clones, these reagents exhibit unmatched specificity toward individual epitopes on pupylated targets. Their uniform performance across experimental batches supports standardized applications requiring precise molecular targeting.
Site-Specific Anti-Pupylation Antibodies: These are designed to detect pupylation at a particular amino acid or within a specific protein sequence. These are key for understanding the effects of pupylation at specific locations. We often use custom-made peptides with the Pup modification at the target site to generate these.
Pan Anti-Pupylation Antibodies: Designed to recognize Pup irrespective of its attachment site or host protein, these antibodies provide system-wide detection capabilities. Generated using carrier proteins conjugated with Pup, they serve as versatile reagents for global pupylation profiling across diverse biological samples.
Monospecific Anti-Pupylation Polyclonal Antibody Production
Our protocol for developing pupylation-specific polyclonal antibodies employs systematic antigen design and purification. Animals receive immunizations with synthetic peptides mimicking Pup-modified regions, conjugated to carrier proteins for enhanced immunogenicity. Post-immunization antisera undergoes dual-phase purification: initial depletion of antibodies binding unmodified sequences followed by affinity capture using Pup-conjugated matrices. This yields antibody pools with multi-epitope recognition capabilities, ideal for applications demanding amplified detection signals or preliminary screening where moderate cross-reactivity proves acceptable.
Phage Display Strategy for Anti-Pupylation Monoclonal Antibody Discovery
Phage display offers a powerful approach to discover anti-Pup modification antibodies by screening both immune and non-immune phage-displayed antibody fragment libraries. Lterative biopanning against Pup-modified antigens allows for the efficient isolation of high-affinity binders, while non-specific phages are discarded. Selected clones can be readily converted into full humanized antibodies. This technique excels at uncovering rare, epitope-specific antibodies, especially valuable for targeting transient Pup-induced conformations, and often yields antibodies with enhanced thermal stability and batch consistency compared to traditional hybridoma methods.
Hybridoma Strategy for Anti-Pupylation Monoclonal Antibody Discovery
The established hybridoma approach begins with animal immunization using pupylated antigens to activate B-cell populations. Post-immune spleen cells fuse with myeloma partners, creating immortalized antibody factories. High-throughput screening identifies clones secreting Pup-specific antibodies, which undergo clonal expansion for large-scale production. While requiring more resources than phage display, this method reliably generates antibodies with proven in vivo functionality and long-term stability, critical for therapeutic development or longitudinal studies.
Custom Design of Pupylation-Specific Immunogens: Tailoring immunogen structure for optimal antibody recognition of the Pup modification.
Epitope Mapping for Site-Specific Antibody Development: Precisely defining antibody binding sites on pupylated proteins.
Affinity Maturation for Enhanced Antibody Binding: Optimizing antibody affinity for superior detection sensitivity.
Comprehensive Antibody Characterization for Pupylation Specificity: Rigorous validation to ensure exclusive binding to pupylated targets.
Scalable Antibody Production for Research and Diagnostics: Offering flexible production volumes of your custom pupylation antibodies.
Q: Given pupylation's novelty, how reliable are your antibodies?
A: Our confidence stems from parallel expertise in bacterial modification systems. Though pupylation research remains emerging, our antigen design incorporates conserved prokaryotic PTM features while integrating Pup-specific structural insights. Validation protocols include cross-checking against evolutionarily related modifiers to ensure specificity.
Q: Generating stable and well-defined pupylated antigens can be challenging. How do you address this?
A: We mitigate antigen instability through optimized conjugation chemistries and structural stabilization techniques. All antigens undergo circular dichroism verification for proper folding before immunization. For particularly labile targets, we substitute full-length proteins with constrained peptide-Pup conjugates exhibiting improved shelf stability.
Q: How do you overcome the potential for antibodies to cross-react with the unpupylated form of the target protein?
A: Our counter-screening protocol uses identical antigens lacking Pup modifications. Antibodies showing >5% cross-reactivity get eliminated during primary screening. Subsequent validation employs native protein extracts from Pup-deficient bacterial strains as negative controls.
Q: Site-specific pupylation is often transient or occurs at low levels. Can you still generate antibodies targeting these specific modifications?
A: Yes, through antigen dose fractionation strategies and phage display panning under near-physiological modification densities. For endogenous low-level targets, we amplify immune responses using prolonged immunization schedules with controlled antigen release formulations.
Q: How do you validate the functionality of your pupylation-specific antibodies in biological assays?
A: Validation combines orthogonal methods: co-immunoprecipitation with Pup hydrolase knockout strains, and inhibition assays measuring proteasomal degradation rates. For spatial analysis, we conduct correlative light-electron microscopy mapping of pupylation foci. We can also tailor validation assays to your specific research applications.
Q: Can your antibodies distinguish structurally conserved pupylation across species?
A: Species specificity depends on Pup-flanking sequence divergence. When conservation complicates discrimination, we immunize with chimeric antigens combining target species' Pup sequence with heterologous carrier domains to break immune tolerance. Screening then prioritizes clones recognizing combinatorial epitopes.
References
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
